EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Catalent董事Ryan Michelle R出售价值167,160美元的股票
根据最近的SEC文件显示，Catalent, Inc. (NYSE:CTLT)的董事Ryan Michelle R近期出售了2,800股公司普通股。每股售价为59.70美元，总交易价值为167,160美元。此次出售后，Ryan Michelle R现持有10,835股，包括限制性股票单位。这些股票的出售是为了支付之前根据Catalent非雇员董事薪酬计划授予的限制性股票单位相关的税款。
EU regulators see info from rivals, customers in Catalent sale to Novo Holdings - Reuters
European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.
EU Regulators Quiz Novo Nordisk, Catalent Rivals on $16.5 Billion Deal
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
ENDPOINTS NEWS14 小时
Eu­ro­pean Com­mis­sion seeks bio­phar­ma feed­back on No­vo-Catal­ent deal — re ...
The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo ...
bovnews5 天
What’s Causing Catalent Inc (CTLT) Stock’s 6.45% Jump Over the Last Six Months?
On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...
devdiscourse16 小时
Global Health: Big Pharma Deals, Diabetes Epidemic, and Opioid Cases
A summary of current health news details EU regulators probing Novo Nordisk's $16.5 billion Catalent takeover, Amgen's ...
devdiscourse19 小时
Innovations and Challenges in Pharma: A Global Health Report
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...